EA
INO icon

Emerald Acquisition’s Inovio Pharmaceuticals INO Stock Holding History

Emerald Acquisition’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$752K Sell
6,724
-12,945
-66% -$1.43M ﹤0.01% 2267
2016
Q2 		$2.18M Buy
+19,669
New +$2.39M ﹤0.01% 1780

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Emerald Acquisition's INO Position: Q3 2016 in Review

Emerald Acquisition reduced its Inovio Pharmaceuticals (INO) stake by 66% in Q3 2016, selling an estimated $1.43M and leaving 6,724 shares worth $752K. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Emerald Acquisition first reported a position in INO in Q2 2016 and has held it in 2 quarters since. The position peaked at $2.18M in Q2 2016. 125 funds tracked by Wall St. Rank hold INO as of Q3 2016.

  • Emerald Acquisition held 6,724 shares of Inovio Pharmaceuticals worth $752K as of Q3 2016.
  • Emerald Acquisition sold 12,945 Inovio Pharmaceuticals shares in Q3 2016, an estimated $1.43M.
  • Inovio Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2267 holding.
  • Emerald Acquisition first reported a position in Inovio Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Inovio Pharmaceuticals position peaked at $2.18M in Q2 2016.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.